Preparation and quality control of lutetium-177 bleomycin as a possible therapeutic agent

Nukleonika

Volumn 55, Issue 3, 2010, Pages 285-291

  Yousefnia, Hassan ^a   Jalilian, Amir R ^a   Zolghadri, Samaneh ^a   Bahrami Samani, Ali ^a   Shirvani Arani, Simindokht ^a   Ghannadi Maragheh, Mohammad ^a  

^a NUCLEAR SCIENCE AND TECHNOLOGY RESEARCH INSTITUTE   (Iran)

Author keywords

Biodistribution; Bleomycin; Lu 177; Radiolabeling

Indexed keywords

EID: 79960877971     PISSN: 00295922     EISSN: 15085791     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Bahrami-Samani A, Ghannadi-Maragheh M, Jalilian AR, Mazidi M (2010) Biological studies of samarium-153 bleomycin complex in human breast cancer murine xenografts for therapeutic applications. Radiochim Acta 98:237-242
2. Bodei L, Ferone D, Grana CM et al. (2009) Peptide receptor therapies in neuroendocrine tumors. J Endocrinol Invest 2;4:360-369
3. Brooks RC, Canochan P, Vollano JF, Powel NA, Zwiet J (1999) Metal complexes of bleomycin: evaluation of [Rh-105]-Bleomycin for use in targeted radiotherapy. Nucl Med Biol 26:421-430
4. 177Lu--EDTMP: a viable bone pain palliative in skeletal metastasis. Cancer Biother Radiopharm 23;2:202-213
5. 177Lu-labelled hydroxyapatite as a promising agent for radiation synovectomy of small joints. Nucl Med Commun 27;8:661-668
6. 177Lu-labeled hydroxyapatite particles for possible use in the therapy of liver cancer. Nucl Med Biol 35;5:589-597
7. IAEA (2003) Manual for reactor produced radioisotopes. IAEA-TECDOC-1340. International Atomic Energy Agency, Vienna
8. 62Zn]bleomycin as a possible PET tracer. Nukleonika 50:143-148
9. 66Ga]Bleomycin complex as a possible PET radiopharmaceutical. J Radioanal Nucl Chem 264:617-621
10. 201Tl] (III)-Bleomycin for tumor imaging. Radiochim Acta 94:453-459
11. Jalilian AR, Zandi H, Sardari D et al. (2009) Preparation and biological evaluation of [Cu-61]bleomycin complex as a possible PET radiopharmaceutical. Nukleonika 54:135-141
12. 111In-labelled bleomycin complex for the differentiation of high- and low-grade gliomas. Nucl Med Commun 20:145-152
13. Lenkinski RE, Peerce, BE, Pillai MRI, Glickson JD (1980) Calcium(II) and the trivalent lanthanide ion complexes of the bleomycin antibiotics. Potentiometric, fluorescence and proton NMR studies. J Am Chem Soc 102:7088-7093
14. Melnyk DL, Horwitz SB, Peisach T (1987) The oxidation--reduction potential of copper-bleomycin. Inorg Chim Acta 138:75-78
15. 177Lu-antibody conjugates for single--cell kill of B-lymphoma cells in vitro and for therapy of micrometastases in vivo. Nucl Med Biol 32:269-278
16. Reynolds JE, Martindale I (ed) (1996) The extra pharmacopoeia, 31st ed. Royal Pharmaceutical Society, London, pp 546-547
17. Stern PH, Halpern SE, Hagan PL, Howell SB, Dabbs JE, Gordon RM (1981) Cytotoxic activity, tumor accumulationand tissue distribution of ruthenium-103-labeled--bleomycin. J Nat Cancer Inst 66:807-811
18. Sullivan JC, Friedman AM, Rayudu GVS, Fordham EW, Ramachandran PC (1075) Tumor localization studies with radioactive lanthanide and actinide complexes. J Nucl Med Biol 2:44-45
19. Takita T, Umezawa Y, Saito SI et al. (1982) Retrosynthetic manipulation of bleomycins. Tetrahedron Lett 123:521-524
20. Umezawa HT, Takeuchi S, Hori T (1972) Studies on the mechanisms of anti-tumor effects of bleomycin on squamous cell carcinoma. J Antibiot 7:409-420
21. Wenzel TJ, Zomlefer K, Rapkin SA, Keith RH (1995) Lanthanide luminescence detection of bleomycins and nalidixic acid. J Liquid Chromat Rel Technol 18:1473-1486